These three gems are packed with potential
News & Analysis: CRISPR Therapeutics
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
A big day in biotech helped lift the market.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.
The latest gene therapy to flop in a clinical trial pulled CRISPR stocks down with it.
A huge downgrade for this gene-editing biotech still has a nice silver lining.
Clinical trial readouts on the way will move these stocks before 2019's finished.
Which of these gene-editing stocks has the best chance to boost your portfolio?
Citigroup has downgraded the gene-editing pioneer to "sell," but Wall Street has been known to make mistakes.